4267

antibody from Cell Signaling Technology, Inc

Targeting: EGFR ERBB, ERBB1

Western blot (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Flow cytometry (Data presented on provider website)

Antibody Data

Product number

4267

Provider

Cell Signaling Technology, Inc

Proper citation

Cell Signaling Technology Cat#4267, RRID:AB_2246311

Product name

EGF Receptor (D38B1) XP® Rabbit mAb

Antibody type

Monoclonal

Reactivity

Human, Mouse, Simian

Host

Rabbit

Storage

-20°C

References

Submitted references

xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.

Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O
Cancer research 2013 Mar 15;73(6):1855-66

---

Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling.

Koga H, Tsedensodnom O, Tomimaru Y, Walker EJ, Lee HC, Kim KM, Yano H, Wands JR, Kim M
PloS one 2012;7(6):e39981

---

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.

Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Aug 15;18(16):4449-57

---

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.

Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, Aizawa H, Basaki Y, Kuwano M, Kage M, Mitsudomi T, Ono M
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jun 15;16(12):3163-70

---

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.

Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M
The American journal of pathology 2010 Jul;177(1):415-23

---

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.

Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X, Comb MJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 May 1;15(9):3023-8